Why the study?
Biomarker-based models predicting death risk in HFrEF are useful, motivating a new model combining clinical characteristics, NT-proBNP, and oxidative stress markers for routine clinical practice.
Does a predictive model combining clinical characteristics, NT-proBNP, and oxidative stress markers predict post-discharge mortality in patients with HFrEF?
Does a predictive model combining clinical characteristics, NT-proBNP, and oxidative stress markers predict post-discharge mortality in patients with HFrEF?
A novel predictive model incorporating oxidative stress markers (TAC, UA) alongside NT-proBNP and clinical variables provides good discriminatory power for predicting post-discharge mortality in HFrEF patients.
Answers are grounded in this paper and cite their sources.
May aid post-discharge risk stratification in HFrEF; hypothesis-generating and requires prospective validation before clinical adoption.
Background: Current predictive models based on biomarkers reflective of different pathways of heart failure with reduced ejection fraction (HFrEF) pathogenesis constitute a useful tool for predicting death risk among HFrEF patients. The purpose of the study was to develop a new predictive model for post-discharge mortality risk among HFrEF patients, based on a combination of clinical patients' characteristics, N-terminal pro-B-type Natriuretic peptide (NT-proBNP) and oxidative stress markers as a potentially valuable tool for routine clinical practice. Methods: 116 patients with stable HFrEF were recruited in a prospective single-center study. Plasma levels of NT-proBNP and oxidative stress markers [superoxide dismutase (SOD), glutathione peroxidase (GPX), uric acid (UA), total bilirubin (TB), gamma-glutamyl transferase (GGT) and total antioxidant capacity (TAC)] were measured in the stable predischarge condition. Generalized linear model (GLM), random forest and extreme gradient boosting models were developed to predict post-discharge mortality risk using clinical and laboratory data. Through comprehensive evaluation, the most performant model was selected. Results: During a median follow-up of 525 days (7-930), 33 (28%) patients died. Among the three created models, the GLM presented the best performance for post-discharge death prediction in HFrEF. The predictors included in the GLM model were age, female sex, beta blockers, NT-proBNP, left ventricular ejection fraction (LVEF), TAC levels, admission systolic blood pressure (SBP), angiotensin-converting enzyme inhibitors/angiotensin receptor II blockers (ACEI/ARBs) and UA levels. Our model had a good discriminatory power for post-discharge mortality [The area under the curve (AUC) = 74.5%]. Based on the retained model, an online calculator was developed to allow the identification of patients with heightened post-discharge death risk. Conclusion: In conclusion, we created a new and simple tool that may allow the identification of patients at heightened post-discharge mortality risk and could assist the treatment decision-making.
No takes yet. Share an insight, caveat, or question.
Gtif et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: